13203CA224-098-NCT05002569OpenA Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV MelanomaCA224098NCT05002569IndustryAdultTreatmentIIIMelanoma, SkinGibney, GeoffreyGeorgetown University Medical Center : Gayle Cramer; Lombardi Comprehensive Cancer Center : Gayle CramerMelanomaOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS- 6887Gayle CramerGayle Cramer+1 202-687-1116gc604@georgetown.eduClinical Research Nurse 2
2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>